Pfizer Inc. has said it will discontinue development of its closely watched obesity pill, danuglipron, dealing a severe blow to the company’s ambitions to...
Increased manufacturing capacity for Eli Lilly’s highly sought after weight-loss drug Zepbound drove the company to raise its annual sales forecast by $3 billion...
The world has long been concerned about obesity.It has long been known for its connections to non-communicable diseases like diabetes, cardiovascular disease, and hypertension.Initially presented...